TS-172
Phase 3Small molecule
TS-172 is one of 27 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 3.
2
Indications
12
Total Trials
3
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Hepatic Impairment
#DrugCompanyPhaseTrials
1Vanflyta
Daiichi SankyoPhase 1
TS-172
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Beqalzi
BBeOne Medicines
Phase 1
Luye
Ascentage Pharma Group Inc.Phase 1
Gomekli
SSpringWorks Therapeutics, Inc.
Phase 1
DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 1
Lipaglyn
ZZydus Therapeutics Inc.
Phase 1
Casdatifan
Arcus BiosciencesPhase 1
ASTX727
Taiho Oncology, Inc.Phase 1
PF-07328948
PfizerPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperphosphatemia5 trials
Adult Subject3 trials
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS-172. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTaisho Pharmaceutical Co., Ltd.